Job Trends
Rampart Bioscience was working on a platform to deliver gene therapies without the need for viral vectors.
Labor Market Reports
BioSpace’s Q3 2025 U.S. Life Sciences Job Market Report reveals a turbulent quarter for biopharma hiring, with record declines in job postings, rising layoffs, and cautious employer sentiment shaping the industry’s employment landscape.
BioSpace data show biopharma professionals faced increased competition for fewer employment opportunities during the second quarter of 2025, with increased pressure from further layoffs.
Establishing trust through thought leadership is no longer optional in today’s cautious biopharma market. Learn how strategic insights and targeted outreach can turn awareness into high-converting leads.
Now Hiring
Looking for a new opportunity in New Jersey? These nine companies have open roles that could be a great fit for you.
Job listings in the area have ticked up in the last month. These seven companies are hiring in South San Francisco right now, including scientist and clinical roles.
Looking for a biopharma job in New York? Check out the BioSpace list of eight companies hiring life sciences professionals like you.
Career Advice
Clarity on employment terms is essential to protect careers. In this column, Kaye/Bassman’s Michael Pietrack speaks to employment attorney Howard Matalon, JD, partner at OlenderFeldman, on how to evaluate the fine print of an employment agreement.
THE LATEST
Shire will have its new CFO in March.
All of the recent problems have caused the company’s largest shareholder to push for a sale.
Fresh off its $7B acquisition, Celgene is planning to open a biopharma incubator on its corporate campus in New Jersey.
Investors and analysts have given it some thought and mostly think it’s a sensible acquisition.
The USPTO is paving the way for generic challengers to J&J’s prostate cancer drug Zytiga.
On Jan. 8, Alder BioPharma announced that its eptinezumab met its primary endpoint in its Phase III PROMISE 2 clinical trial for preventing migraine.
The rumors have caused Juno’s stock to rocket more than 50 percent to $68.80 in premarket trading.
Thirty years ago, neurologist Leonard S. Schliefer, MD, PhD, founded Regeneron, a life sciences company dedicated to discovering, developing and bringing new medications to the patients who need them.
The new space for biotechs is available following investments from Alexandria Real Estate Equities in this city.
Merck’s Keytruda has done it again.